Carisma Therapeutics
Delivering macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
Launch date
Employees
Market cap
€38.5m
Enterprise valuation
€9m (Public information from Sep 2024)
Share price
$0.981 CARM
Philadelphia Pennsylvania (HQ)
Authorizing premium user...